#How to you pronounce john petrucci trial#
#How to you pronounce john petrucci plus#

The tandem transplant phase applied melphalan 200 mg/m 2 (MEL200) 3–6 months apart those over the age of 69 years and with renal insufficiency (creatinine >176.8 μmol/l) were given a lower melphalan dose of 140 mg/m 2 (MEL140) in case of less than partial response (PR) prior to the second transplant, the BEAM regimen (carmustine, etoposide, cytarabine, melphalan) was applied with the second transplant ( Ramasamy et al, 2004).

#How to you pronounce john petrucci plus#

Induction consisted of VAD (vincristine-doxorubicin-dexamethasone) ( Barlogie et al, 1984), DCEP (dexamethasone plus 4 d continuous infusions of cyclophosphamide, etoposide, cis-platin) ( Desikan et al, 1999), CAD (4 d continuous infusions of cyclophosphamide, doxorubicin plus dexamethasone) for peripheral blood stem cell (PBSC) collection and further DCEP. Briefly, TT2 consisted of four phases ( Fig 1). The details of TT2 have been published previously ( Barlogie et al, 2006a). The TT2 outcome data are also examined in the context of the predecessor protocol, total therapy 1 (TT1), a tandem transplant program without consolidation chemotherapy ( Barlogie et al, 1997) ( Barlogie et al, 2006b, c). With a median follow-up of 6 years for live patients, we now report on a final analysis of the 668 patients enrolled and address the role of THAL for subgroups with different risk features prior to TT2 and whether patients completing the intended consolidation therapy derived EFS and OS benefit compared to those who either did not qualify due to thrombocytopenia or lack of antitumour effect from chemotherapy during the induction phase.

#How to you pronounce john petrucci trial#

An additional novel feature of the trial was the introduction of consolidation chemotherapy post-transplant in an attempt to delay or even prevent recurrence. Results indicated that, while CR and event-free survival (EFS) were superior on the THAL versus no THAL arm, overall survival (OS) was not extended by the addition of THAL. We have previously reported on total therapy 2 (TT2), a tandem transplant trial that addressed, in a randomized trial design, the role of thalidomide (THAL) in improving complete response (CR) and extending survival ( Barlogie et al, 2006a). These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design. Adjusting for prognostic variables in multivariate and pair-mate analyses, TT2 was superior to TT1 in terms of CR duration, event-free and overall survival. TT2's major advance vis-à-vis TT1 pertained to the subgroup without cytogenetic abnormalities (CA), supporting the role of post-transplant consolidation therapy, whereas the improved survival of the CA subgroup on the experimental versus control arm of TT2 attests to the role of THAL in this setting. Event-free and overall survivals were extended from 2.6 to 5.7 years, respectively, with TT1 to 4.8 and 8.0 years with TT2. CR durations were similar with either TT2 arm and both were superior to results of TT1. Complete response (CR) rates were similar at 40% for TT1 and TT2 without THAL versus 60% on the THAL arm of TT2. With median follow-up times of 5 and 12 years, respectively, outcome comparisons were made of 668 patient's enrolled on TT2 and 231 patients treated on TT1. article/BOOK+REVIEWS/1528503/178543/article.In comparison to total therapy 1 (TT1), the phase 3 trial total therapy 2 (TT2) evaluated the benefit of up-front administration of thalidomide (THAL) TT2 also introduced post-transplant consolidation chemotherapy.

Scottish Rite - Nov/Dec 2013 BOOK REVIEWS